Literature DB >> 9248735

The concentration of u-PA and PAI-1 antigen in tissue extracts of nasopharyngeal carcinoma.

M Sunagawa1, G W Huang, M Nakamura, T Kosugi.   

Abstract

We measured the antigen levels of urokinase-type plasminogen activator (u-PA) and plasminogen activator inhibitor-1 (PAI-1) in tissue extracts from nasopharyngeal carcinomas. An increase in u-PA antigen was observed with the advanced stages of disease. However, the levels of PAI-1 antigen decreased with each advanced stage. These results suggest that local administration of antiplasminic agents may be effective in suppressing tumor invasion.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9248735     DOI： 10.1007/bf02905987

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN： 0937-4477            Impact factor:   2.503


  12 in total

1.  Identification of a plasminogen activator derived from nasopharyngeal carcinoma.

Authors:  T Kosugi; G W Huang; M Nakamura; S Koja; H T Nong
Journal:  Eur Arch Otorhinolaryngol       Date:  1990       Impact factor: 2.503

Review 2.  The plasminogen activator/plasmin system.

Authors:  J D Vassalli; A P Sappino; D Belin
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

4.  Plasminogen activator inhibitor 1 (PAI) is bound to vitronectin in plasma.

Authors:  B Wiman; A Almquist; O Sigurdardottir; T Lindahl
Journal:  FEBS Lett       Date:  1988-12-19       Impact factor: 4.124

5.  [New and changed guidelines in the TNM system of head and neck tumors].

Authors:  W Schwab; B Clasen; H J Steinhoff
Journal:  HNO       Date:  1987-03       Impact factor: 1.284

Review 6.  Cell-associated plasminogen activation: regulation and physiological functions.

Authors:  O Saksela; D B Rifkin
Journal:  Annu Rev Cell Biol       Date:  1988

7.  The urokinase type of plasminogen activator in cancer of digestive tracts.

Authors:  N Nishino; K Aoki; Y Tokura; S Sakaguchi; Y Takada; A Takada
Journal:  Thromb Res       Date:  1988-05-15       Impact factor: 3.944

8.  Plasminogen activator secretion of human tumors in short-term organ culture, including a comparison of primary and metastatic colon tumors.

Authors:  G Markus; S M Camiolo; S Kohga; J M Madeja; A Mittelman
Journal:  Cancer Res       Date:  1983-11       Impact factor: 12.701

Review 9.  Plasminogen activator inhibitor type 1 in cancer: therapeutic and prognostic implications.

Authors:  H Pappot; H Gårdsvoll; J Rømer; A N Pedersen; J Grøndahl-Hansen; C Pyke; N Brünner
Journal:  Biol Chem Hoppe Seyler       Date:  1995-05

10.  Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination.

Authors:  M Nagayama; A Sato; H Hayakawa; T Urano; Y Takada; A Takada
Journal:  Cancer       Date:  1994-03-01       Impact factor: 6.860
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.